Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development.
In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to reach $112 billion in 2017.
That’s mostly due to increased research and development, new technology, additional regulatory easing, and new product launches, and the ability of pharmaceutical companies to use orphan drugs for off-label uses is also helping in achieving market growth.
As this market trend also becomes global, there has been more interest from the industry drivers to meet, dialogue and brainstorm about the current challenges and opportunities involved in delivering new orphan drugs to rare disease patients. The World Orphan Drug Congress USA has been for the past 3 years the central gathering of all stakeholders from this industry.
On August 1st the conference will be featured in the segment Behind the Mystery, Rare and Genetic Diseases of the TV show The Balancing Act on Lifetime TV. Make sure you’ll watch it to stay abreast of the updates for the exciting 2014 edition of the conference.
You don’t want to miss it! See you in 2014 in Washington DC!